• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    10/13/23 9:06:02 AM ET
    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email

    Gainers

    • Bio-Path Hldgs (NASDAQ:BPTH) stock rose 132.2% to $0.92 during Friday's pre-market session. The company's market cap stands at $10.4 million.
    • Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 34.4% to $0.5. The company's market cap stands at $2.9 million.
    • Akari Therapeutics (NASDAQ:AKTX) shares rose 14.52% to $4.02. The market value of their outstanding shares is at $20.3 million.
    • TRACON Pharma (NASDAQ:TCON) stock moved upwards by 14.42% to $0.22. The market value of their outstanding shares is at $6.7 million.
    • Petros Pharma (NASDAQ:PTPI) shares increased by 13.94% to $1.74. The company's market cap stands at $3.6 million.
    • Sera Prognostics (NASDAQ:SERA) shares increased by 12.76% to $2.12. The company's market cap stands at $66.3 million.

    Losers

    • Outset Medical (NASDAQ:OM) shares declined by 39.3% to $4.11 during Friday's pre-market session. The market value of their outstanding shares is at $204.6 million.
    • Nuwellis (NASDAQ:NUWE) shares decreased by 35.15% to $0.66. The market value of their outstanding shares is at $1.2 million.
    • Bellerophon Therapeutics (NASDAQ:BLPH) shares decreased by 31.86% to $0.26. The company's market cap stands at $3.2 million.
    • Cassava Sciences (NASDAQ:SAVA) shares decreased by 29.88% to $12.3. The market value of their outstanding shares is at $516.2 million.
    • OpGen (NASDAQ:OPGN) shares fell 25.1% to $0.69. The market value of their outstanding shares is at $6.1 million.
    • Reshape Lifesciences (NASDAQ:RSLS) shares decreased by 16.18% to $0.28. The market value of their outstanding shares is at $1.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX
    $BLPH
    $BPTH
    $NUWE

    CompanyDatePrice TargetRatingAnalyst
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    Sera Prognostics Inc.
    $SERA
    12/15/2025$5.00Buy
    Jefferies
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    Cassava Sciences Inc.
    $SAVA
    11/26/2024Buy → Neutral
    H.C. Wainwright
    Cassava Sciences Inc.
    $SAVA
    10/8/2024$116.00Neutral → Buy
    H.C. Wainwright
    Outset Medical Inc.
    $OM
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    Nuwellis Inc.
    $NUWE
    7/29/2024$17.00Buy
    ROTH MKM
    Cassava Sciences Inc.
    $SAVA
    7/1/2024Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    2/26/26 8:49:40 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 1-Z filed by Bio-Path Holdings Inc.

    1-Z - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    2/25/26 4:44:21 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Harrison Robert Gardner sold $4,680 worth of shares (2,000 units at $2.34), decreasing direct ownership by 2% to 80,788 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    2/24/26 6:10:55 PM ET
    $SERA
    Medical Specialities
    Health Care

    General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    2/19/26 8:57:47 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    2/19/26 8:57:07 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/20/25 5:39:26 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. E

    1/26/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $AKTX
    $BLPH
    $BPTH
    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care